Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin
| Autor: | Paulo Sergio Pereira Junior, Mariana Ragassi Urbano, Eliana Cotta de Faria, Tania L Mazzuco, Aline Franco da Rocha, Helena Kaminami Morimoto, Alexandre J. F. Carrilho, Gabriela Simonetti Calefi, Guilherme Figueiredo Marquezine |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Prediabetic State 03 medical and health sciences 0302 clinical medicine Endocrinology Glucosides Internal medicine Diabetes mellitus Ketogenesis medicine Empagliflozin Humans Hypoglycemic Agents Prediabetes Benzhydryl Compounds business.industry Insulin Glucagon secretion Type 2 Diabetes Mellitus medicine.disease Diabetes Mellitus Type 2 030220 oncology & carcinogenesis Growth Hormone Pegvisomant Female business medicine.drug |
| Zdroj: | Endocrine. 73(2) |
| ISSN: | 1559-0100 |
| Popis: | Sodium-glucose cotransporter 2 inhibitors increase glucagon secretion by pancreatic alpha cells and the susceptibility to ketoacidosis. On the other hand, growth hormone (GH) stimulates peripheral lipolysis and provides free fatty acids (FFA) for ketogenesis; however, it remains unresolved whether GH directly impacts hepatic ketogenesis. We aimed to investigate the role of physiologic GH levels in promoting ketogenesis in prediabetic or type 2 diabetic patients under empagliflozin treatment. Sixteen patients (11 women, 5 men) with prediabetes or type 2 diabetes mellitus, aged 55.6 ± 4.7 years and with a mean BMI of 30.7 ± 4.8 kg/m2 and HbA1c 7.1 ± 1.6% (means ± SD), participated in this study. All of them were submitted to three mixed-meal tests: they received placebo at −60 min (test 1), and empagliflozin 25 mg (test 2, 21st day) and empagliflozin 25 mg plus pegvisomant 30 mg were administered subcutaneously 36 h before (test 3, 28th day). After test 1, all patients were instructed to take empagliflozin 25 mg daily. The empagliflozin treatment decreased the plasma concentrations of glucose by 14% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink